Hyperthermia and immunity. A brief overview
/in Hypernephroma, Hyperthermia, International Publications, Malignant MelanomaSensitive detection of human papillomavirus type 16 E7-specific T cells by ELISPOT after multiple in vitro stimulations of CD8+ T cells with peptide-pulsed autologous dendritic cells
/in Cervical Cancer, International PublicationsIn vitro assessment of dendritic cells pulsed with apoptotic tumor cells as a vaccine for ovarian cancer patients
/in Dendritic Cells, International Publications, Ovarian CancerProduction of interferons by dendritic cells, plasmacytoid cells, natural killer cells, and interferon-producing killer dendritic cells
/in Dendritic Cells, International PublicationsCombined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid
/in Brain Tumors in Children, Glioblastoma, International Publications, Newcastle Disease VirusDendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses
/in Acute Leukemia, International Publications[Clinical impact of locoregional hyperthermia in gynecological oncology]
/in Breast Cancer, Cervical Cancer, Hyperthermia, International PublicationsCurrent status of immunotherapy in B cell malignancies
/in Chronic Leukemia, Dendritic Cells, International Publications, Malignant Lymphoma, Multiple Myeloma
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer